Viking Therapeutics has significantly expanded its fundraising efforts, announcing the pricing of two concurrent public offerings totaling roughly 500 million dollars. This move marks a notable increase from the company’s original plans, which initially aimed for smaller targets of 200 million dollars for both common stock and convertible senior notes. By upping these figures, the clinical stage biopharmaceutical firm is positioning itself with a substantial war chest to fuel its ambitious pipeline of treatments for metabolic and endocrine disorders.
The financial structure of the deal includes the sale of nearly 7.9 million shares of common stock priced at 35 dollars per share. Alongside this equity raise, Viking is issuing 225 million dollars in convertible senior notes due in 2032, carrying an annual interest rate of 2 percent. These notes offer investors a path to convert their debt into equity starting in mid 2032, provided certain conditions are met, reflecting confidence in the long term growth potential of the company’s portfolio.
Management intends to funnel the vast majority of these funds into the acceleration of its key drug candidates. Specifically, the proceeds are earmarked for the ongoing clinical development and eventual commercialization of its VK2735 program, as well as further advancement of the VK3019 program. A portion of the capital will also be reserved for general research and development needs and overall working capital to sustain operations during critical trial phases.
A heavy hitting group of financial institutions managed the process, including Morgan Stanley and J.P. Morgan among others who acted as joint book running managers for both portions of the offering. While some options remain for underwriters to purchase additional shares or notes to cover over allotments, the core deals are expected to settle on September 25, pending standard closing conditions. The independence of the two offerings ensures that neither depends on the success of the other to reach completion.